Cannabis and Arthritis: What the Research Says (2026)

By James Buddsey · Updated October 14, 2026

Research on cannabis for arthritis is thin: one small trial of a THC/CBD mouth spray found a modest drop in rheumatoid arthritis pain, while three placebo-controlled trials of CBD in osteoarthritis and psoriatic arthritis found no benefit over placebo. Cannabis does have stronger evidence for chronic pain in general, but no cannabis product is approved to treat arthritis, and none slows joint damage.

Arthritis is one of the most common reasons people walk into a dispensary or buy a CBD cream. The marketing suggests the science is settled. It is not. This guide walks through what the studies actually show for rheumatoid arthritis (RA), osteoarthritis (OA) and psoriatic arthritis, what the medical societies say, and how to think about the risks if you are considering cannabis alongside your regular treatment. For the wider research picture, see our cannabis research hub.

Evidence at a Glance: Cannabis and Arthritis

Does Cannabis Help Arthritis Pain?

The honest answer is “possibly a little, for some people, with side effects.” The strongest evidence is not about arthritis specifically. The National Academies of Sciences, Engineering, and Medicine concluded in 2017 that there is substantial evidence cannabis and cannabinoids are effective for chronic pain in adults. Most of the trials behind that conclusion involved nerve pain and multiple sclerosis, not inflamed or worn joints.

When researchers narrow the question to arthritis, the evidence shrinks fast. A 2016 systematic review of rheumatic disease pain by Fitzcharles and colleagues found only four qualifying randomized trials across fibromyalgia, back pain, osteoarthritis and RA, with none in osteoarthritis at the time. The authors concluded there was not enough evidence to recommend any cannabinoid product for these conditions.

Rheumatoid Arthritis: The One Small Positive Trial

The study most often cited for RA is a 2006 trial in Rheumatology led by David Blake. Fifty-eight patients were randomized to Sativex (nabiximols), a mouth spray containing roughly equal THC and CBD, or to placebo for five weeks. The spray group reported statistically significant improvements in pain on movement, pain at rest and sleep quality, and a small improvement in a disease activity score. Morning stiffness did not change.

That result is real but modest. A 2012 Cochrane review of pain treatments in RA judged the trial small and low quality. The pain difference was less than one point on the scale used, and people on the spray were significantly more likely to have side effects, mostly dizziness and dry mouth. The Cochrane authors concluded that for oromucosal cannabis “the potential harms seem to outweigh any modest benefit.” No larger RA trial has replaced it since.

The idea that CBD might calm the immune attack in RA comes mainly from a 2000 study in mice. Malfait and colleagues gave CBD to mice with collagen-induced arthritis and found it blocked disease progression and protected the joints, with the best effect at a middle dose. That is a useful lead for drug developers. It does not show the same thing happens in people taking store-bought CBD.

Osteoarthritis and CBD: Recent Trials Came Up Empty

Osteoarthritis, the wear-related joint disease that affects knees, hips and hands, is where CBD marketing is most aggressive. It is also where recent controlled trials have been most disappointing:

• Knee OA, Vienna, 2023. In a trial in Lancet Regional Health Europe, 86 people with painful knee OA took 600 mg of oral CBD a day or placebo for eight weeks on top of acetaminophen. Pain fell about equally in both groups. Side effects were more common with CBD, and liver enzyme rises were three times as frequent (15 vs 5 participants). The authors wrote that their results “do not support” CBD as a pain supplement in knee OA.
• Hand OA and psoriatic arthritis, Denmark, 2022. A 12-week trial in Pain randomized 136 patients to 20 to 30 mg of synthetic CBD daily or placebo. The difference in pain between groups was essentially zero, and sleep, anxiety and depression scores did not differ either.
• Knee OA, CBD-rich cannabis oil, 2025. A placebo-controlled trial published in Frontiers in Pharmacology found both groups improved by similar amounts. The oil was well tolerated but no better than placebo.

Strong placebo responses are common in arthritis pain studies, which is why uncontrolled reports and customer reviews are such a poor guide. Many people feel better after starting CBD; the trials suggest most of that relief would have come anyway.

What About THC Products and Topicals?

Products containing THC are a different matter from CBD alone. The general chronic pain evidence mostly involves THC or THC/CBD combinations, and some arthritis patients report that a small dose at night helps sleep. The Arthritis Foundation suggests that if CBD alone fails and THC is legal where you live, a very low dose of THC can be discussed with your doctor, taken at home or at bedtime because even small amounts can impair you.

Creams, balms and patches are popular because they feel targeted. There are no high-quality trials showing a cannabis topical reduces arthritis pain more than a plain moisturizing rub. If you want to understand how dose and route change the experience, see our cannabis dosage guide.

What Medical Groups Recommend

The Arthritis Foundation’s guidance, written with rheumatologists, is the most practical advice available for patients:

• CBD “is not a substitute for disease-modifying treatment for inflammatory arthritis.” Stopping methotrexate or a biologic to try CBD risks permanent joint damage.
• Talk first to the clinician who manages your arthritis, and keep a diary of dose and symptoms.
• If you try CBD, start low (the Foundation suggests 5 to 10 mg under the tongue twice a day) and raise the dose slowly. Stop if there is no benefit after several weeks.
• Buy only products with a batch-specific certificate of analysis from an independent lab, because labels are often inaccurate.

Risks and Side Effects

• Drug interactions. CBD and THC are processed by liver enzymes that handle many arthritis drugs. The Arthritis Foundation lists possible interactions with NSAIDs, acetaminophen, corticosteroids, tofacitinib, celecoxib, tramadol, gabapentin, pregabalin, some antidepressants and warfarin.
• Liver effects. CBD can raise liver enzymes, as the knee OA trial showed. That matters for people who also take methotrexate or leflunomide, both of which require liver monitoring.
• Dizziness and falls. Dizziness was the most common side effect in the RA spray trial. For older adults with joint problems, a fall can be a serious injury.
• Impairment. THC affects coordination and reaction time. Do not drive after using it.
• Smoking. Smoked cannabis is linked to worse respiratory symptoms and more bronchitis episodes, according to the National Academies. Our guide to the healthiest ways to use cannabis compares the options.

Talk to Your Doctor

Bring a list of every medication and supplement, and ask specific questions: Could CBD or THC interact with my DMARD, biologic or blood thinner? Do I need liver tests? What would count as a meaningful improvement, and how long should I try before stopping? A rheumatologist will not be surprised by the question; many patients ask it. If you live in Washington or Oregon and decide to buy cannabis, licensed stores test their products, and our Washington and Oregon dispensary directories list stores with their state license numbers. Know the rules first: see Washington marijuana laws.

Cannabis and Arthritis FAQ

For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.